These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29269797)

  • 1. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.
    Ragon BK; Mehta RS; Gulbis AM; Saliba RM; Chen J; Rondon G; Popat UR; Nieto Y; Oran B; Olson AL; Patel K; Hosing CM; Qazilbash MH; Shah N; Kebriaei P; Shpall EJ; Champlin RE; Alousi AM
    Bone Marrow Transplant; 2018 Mar; 53(3):315-325. PubMed ID: 29269797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
    Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
    Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease.
    Pidala J; Kim J; Roman-Diaz J; Shapiro J; Nishihori T; Bookout R; Anasetti C; Kharfan-Dabaja MA
    Ann Transplant; 2010; 15(4):21-9. PubMed ID: 21183872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.
    Schmitt T; Luft T; Hegenbart U; Tran TH; Ho AD; Dreger P
    Bone Marrow Transplant; 2011 Apr; 46(4):580-5. PubMed ID: 20562925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
    Mehta RS; Saliba RM; Jan A; Shigle TL; Wang E; Nieto Y; Ciurea SO; Oran B; Im J; Olson A; Marin D; Qazilbash M; Khouri I; Rondon G; Anderlini P; Rezvani K; Popat U; Kebriaei P; Shpall E; Champlin R; Alousi A
    Transplant Cell Ther; 2021 Mar; 27(3):272.e1-272.e5. PubMed ID: 33781539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
    Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
    Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
    [No Abstract]   [Full Text] [Related]  

  • 8. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease.
    Rashidi A; DeFor TE; Holtan SG; Blazar BR; Weisdorf DJ; MacMillan ML
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2297-2302. PubMed ID: 31325587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentostatin in steroid-refractory acute graft-versus-host disease.
    Bolaños-Meade J; Jacobsohn DA; Margolis J; Ogden A; Wientjes MG; Byrd JC; Lucas DM; Anders V; Phelps M; Grever MR; Vogelsang GB
    J Clin Oncol; 2005 Apr; 23(12):2661-8. PubMed ID: 15837980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
    PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study.
    Jacobsohn DA; Gilman AL; Rademaker A; Browning B; Grimley M; Lehmann L; Nemecek ER; Thormann K; Schultz KR; Vogelsang GB
    Blood; 2009 Nov; 114(20):4354-60. PubMed ID: 19745067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment.
    Arai S; Margolis J; Zahurak M; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2002; 8(3):155-60. PubMed ID: 11939605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
    Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
    Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
    Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
    Front Immunol; 2022; 13():954268. PubMed ID: 35990629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.
    Jacobsohn DA; Chen AR; Zahurak M; Piantadosi S; Anders V; Bolaños-Meade J; Higman M; Margolis J; Kaup M; Vogelsang GB
    J Clin Oncol; 2007 Sep; 25(27):4255-61. PubMed ID: 17878478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
    Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid treatment of acute graft-
    Bacigalupo A; Milone G; Cupri A; Severino A; Fagioli F; Berger M; Santarone S; Chiusolo P; Sica S; Mammoliti S; Sorasio R; Massi D; Van Lint MT; Raiola AM; Gualandi F; Selleri C; Sormani MP; Signori A; Risitano A; Bonifazi F;
    Haematologica; 2017 Dec; 102(12):2125-2133. PubMed ID: 28971905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
    Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
    MacMillan ML; Robin M; Harris AC; DeFor TE; Martin PJ; Alousi A; Ho VT; Bolaños-Meade J; Ferrara JL; Jones R; Arora M; Blazar BR; Holtan SG; Jacobsohn D; Pasquini M; Socie G; Antin JH; Levine JE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):761-7. PubMed ID: 25585275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.